Having advised multiple major pharmaceutical companies on their manufacturing divestment strategy for more than 40 of their manufacturing operations globally, PharmaVentures share good practice guidance in the first of 2 guidance notes covering the main stages of the transactions process: pre-marketing; marketing; dataroom preparation and curation; management presentation and site tour; and negotiation.
Good preparation is key for an efficient and smooth transaction process. It is important to allow sufficient time to prepare in order to avoid delays later in the process. Taking steps to de-risk the divestment is vital, especially when the seller needs to ensure their future production quality and standards remain high in the hands of third parties and future supply is not interrupted.
Fintan Walton, CEO, Mark Andrews, Managing Director, and Jansen Jacob, Vice President, give their expert insight and experiences on life science M&A to positively transform your next divestment.

This content is restricted to members. To view this content please register or login below to view this content.

Register to receive up-to-date information and advice on tax developments within your industry.